Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
By M. Decramer, M. R. Mölken, T. Troosters, C. Herwaarden, R. Pellegrino, D. Olivieri, M. D. Donno, W. Backer, I. Lankhorst, A. Ardia. The Lancet, 2005
638 citations recorded by the source corpus.
Subfields: Emergency Medical Services, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/892706742f76c071f89dc1c74ad2bd557a50356b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution (2023, positive): “Су ществуют, однако, некоторые доказательства того, что у больных ХОБЛ, которых не лечили ингаляционными ГКС, терапия такими муколитиками, как карбоцистеин и N ацетилцистеин, может уменьшить частоту обострений [296, 297, 562] (уровень доказательности В), хотя в Кокрановском обзоре показано, что их в”
- Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. (2015, neutral): “>2 15 (9) 55 (4) 29 (16) 53 (3) 55 (38) 90 (7)”
- The changing faces of glutathione, a cellular protagonist. (2003, background): “For example in COPD patients N-acetylcysteine was shown to decrease the intensity and frequency of exacerbations (Decramer et al., 2005).”